Plus: Supreme Court preserves mifepristone access, rejecting lower-court prohibitions on mail and telehealth distribution.
Australian medical device company NinaMED secured $13.75 million in financing, providing capital for a new non-invasive wearable neuromodulation therapy addressing overactive bladder, which affects 550 million people. This financing round arrives as the Supreme Court preserved women's access to the abortion drug mifepristone, allowing continued mail and telehealth access for patients. The Court rejected lower-court restrictions, maintaining current access pathways for clinicians. Five takes inside, plus a quick-hits roundup.
VIA FemTech Insider
NinaMED secured $13.75 million in financing to develop and commercialize the NiNA System, a non-invasive wearable neuromodulation therapy for overactive bladder (OAB). OAB affects 550 million people worldwide and disproportionately affects women. This funding provides capital for a new femtech solution addressing a prevalent women's health condition.
Read the full story →
— The Luteal Editorial Team
VIA Contemporary OB/GYN
Vella Bioscience will launch its Ebbtide vaginal insert for menstrual discomfort on May 19, 2026. This introduces a new product option for femtech operators addressing menstrual health.
Read the full story →
— The Luteal Editorial Team
VIA STAT News
Rigel Pharma will market the newly approved breast cancer drug Veppanu under a commercialization agreement with Arvinas and Pfizer. Roche received European clearance for a new blood test to detect early Alzheimer’s disease. BridgeBio submitted an application to the FDA for encaleret, a drug treating autosomal dominant hypocalcemia type 1.
Read the full story →
— The Luteal Editorial Team
VIA Endpoints News
The Supreme Court allows the abortion pill mifepristone's continued distribution by mail. The ruling maintains mifepristone's current safety protocols, impacting patients and manufacturers. Clinicians can continue prescribing and dispensing mifepristone under existing guidelines.
Read the full story →
— The Luteal Editorial Team
VIA JAMA Network
A new review discusses the epidemiology, clinical presentation, diagnosis, surgical management, histopathologic and molecular characteristics, and adjuvant treatment for endometrial cancer. Clinicians gain a comprehensive overview of current endometrial cancer management.
Read the full story →
— The Luteal Editorial Team
VIA FemTech Insider
This article is an analysis or commentary on investment trends, highlighted by its title "Why Investors Are Betting Big on Incontinence." This topic is highly relevant to femtech as incontinence predominantly affects women, especially after childbirth or during menopause. The piece offers insights into investments in this area of women's health.
Read the full story →
— The Luteal Editorial Team
